share_log

RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $10

Benzinga ·  Nov 15, 2023 13:47

RBC Capital analyst Gregory Renza maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $6 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment